消化性溃疡治疗药物的全球市场（2023-2030）：规模、份额、成长分析和类型预测（质子帮浦抑制剂（PPI）/组织胺 H2 受体拮抗）

消化性溃疡治疗市场规模预计将从2021年的44亿美元和2022年的46亿美元成长到2030年的64亿美元，预测期内年复合成长率为3.5%。

由于多种因素，消化性溃疡药物市场正在稳步成长。消化性溃疡病是一种常见的胃肠道疾病，罹患全球数百万人，由于消化性溃疡病患病率不断增加、人口高龄化以及吸烟和饮酒等不健康习惯日益增加的生活习惯的推动，市场不断成长。

医疗技术的进步和创新配方的发展也促进了市场的成长。然而，仿製药的可用性和替代治疗方案的出现等因素给市场带来了挑战。儘管如此，由于人们越来越认识到消化性溃疡病早期诊断和有效治疗的重要性，预计市场将会成长。

消化性溃疡药物市场的主要趋势之一是越来越多地采用质子帮浦抑制剂（PPI）作为首选。与其他药物类别相比，质子帮浦抑制剂的卓越功效和安全性推动了这一趋势。 PPI 可以长期缓解症状，并透过抑制胃酸分泌来帮助溃疡癒合。此外，配方的进步提高了 PPI 的生物利用度和患者的依从性。对 PPI 的日益偏好预计将推动对消化性溃疡治疗药物的需求。

本报告调查了全球消化性溃疡治疗药物市场，并提供了市场概况、市场各种影响因素分析、技术和创新趋势、法律制度、市场规模趋势和预测以及各个细分市场和地区。编制了单独的细分、竞争形势、主要企业简介等。

目录

• 执行摘要
• 调查方法
• 母市场分析
  • 市场概况
  • 市场规模
  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
• 关键市场洞察
  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • 启动分析
  • 原料分析
  • 创新矩阵
  • 研发线产品分析
  • 总体经济指标
  • 重点投资分析
  • 关键成功因素
  • 竞争程度
  • 市场动态及展望
    • 市场动态
      • 促进因素
      • 机会
      • 抑制因素
      • 任务
  • 法规状况
  • 波特的分析
  • Skyquest 对未来颠覆的独家见解
• 全球消化性溃疡药物市场：按类型
  • 市场概况
  • 质子帮浦抑制剂 (PPI)
  • 组织胺H2受体拮抗
  • 抗酸剂
  • 抗生素
• 全球消化性溃疡药物市场按地区划分
  • 市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲
• 竞争形势
  • 前5名企业对比
  • 主要企业市场地位
  • 主要企业的招募策略
  • 关键成功策略
  • 近期市集活动
  • 主要企业市场占有率
• 主要企业简介
  • MedicoPharm Ltd.
  • Pharmanova Inc.
  • Gastrotech Pharmaceuticals
  • BioCure Pharmaceuticals
  • Medix Corporation
  • PharmaPro Industries
  • Ulcerex Pharma
  • GastroMed Solutions
  • Digesta Pharmaceuticals
  • Healix Pharmaceuticals
  • Pepto Therapeutics
  • Gastronex Ltd.
  • DigestCare Pharmaceuticals
  • Ulcera Pharmaceuticals
  • GastroCure Inc.
  • Stomax Pharmaceuticals
  • Digestive Health Solutions
  • MedicoDigest
  • Gastropedia Pharmaceuticals
  • GastroGenix Corporation

Peptic Ulcer Drugs Market size was valued at USD 4.4 billion in 2021 and is poised to grow from USD 4.6 billion in 2022 to USD 6.4 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).

The global peptic ulcer drugs market is witnessing steady growth due to several factors. Peptic ulcer disease is a common gastrointestinal disorder that affects millions of people worldwide. The market for peptic ulcer drugs is driven by the increasing prevalence of peptic ulcer disease, the growing aging population, and the rising adoption of unhealthy lifestyle habits such as smoking and alcohol consumption.

Additionally, advancements in medical technology and the development of innovative drug formulations have contributed to the growth of the market. However, factors such as the availability of generic drugs and the emergence of alternative treatment options pose challenges to the market. Nonetheless, the increasing awareness about the importance of early diagnosis and effective treatment of peptic ulcers is expected to drive the market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Peptic Ulcer Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Peptic Ulcer Drugs Market Segmental Analysis

The global peptic ulcer drugs market is segmented by type and region. Based on type, the market can be segmented into proton pump inhibitors (PPIs), histamine H2-receptor antagonists, antacids, and antibiotics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Peptic Ulcer Drugs Market Drivers

Increasing Prevalence Of Peptic Ulcers Worldwide

• One driver of the global peptic ulcer drugs market is the increasing prevalence of peptic ulcers worldwide. Peptic ulcers are a common gastrointestinal disorder affecting millions of people, and the demand for effective treatment options is growing. Factors such as unhealthy lifestyles, stress, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) contribute to the rising incidence of peptic ulcers. This drives the demand for peptic ulcer drugs, leading to market growth.

Peptic Ulcer Drugs Market Restraints

Availability Of Alternative Treatment Options

• One restraint of the global peptic ulcer drugs market is the availability of alternative treatment options. In addition to pharmaceutical drugs, there are non-pharmacological approaches such as lifestyle modifications, dietary changes, and natural remedies that are considered effective in managing peptic ulcers. Some individuals may prefer these alternatives, which can impact the demand for traditional peptic ulcer drugs. Moreover, the potential side effects and risks associated with long-term medication use may also lead to concerns among patients and healthcare providers, influencing the market dynamics.

Competitive Landscape for Global Peptic Ulcer Drugs Market

The global peptic ulcer drugs market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Peptic Ulcer Drugs. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.

Market Trends of Global Peptic Ulcer Drugs Key

• One key market trend in the global peptic ulcer drugs market is the increasing adoption of proton pump inhibitors (PPIs) as a preferred treatment option. PPIs are a class of drugs that reduce the production of stomach acid and provide effective relief from peptic ulcers. The trend is driven by the superior efficacy and safety profile of PPIs compared to other drug classes. PPIs offer long-lasting symptom relief and help in healing the ulcers by reducing acid production. Additionally, advancements in drug formulations have improved the bioavailability and patient compliance of PPIs. The growing preference for PPIs is expected to drive the demand for peptic ulcer drugs in the market.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Peptic Ulcer Drugs Market by Type
  • Market Overview
  • Proton pump inhibitors (PPIs)
  • histamine H2-receptor antagonists
  • antacids
  • and antibiotics
• Global Peptic Ulcer Drugs Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • MedicoPharm Ltd. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Pharmanova Inc. (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastrotech Pharmaceuticals (United Kingdom)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • BioCure Pharmaceuticals (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Medix Corporation (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • PharmaPro Industries (France)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Ulcerex Pharma (Canada)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroMed Solutions (Australia)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Digesta Pharmaceuticals (Netherlands)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Healix Pharmaceuticals (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Pepto Therapeutics (Spain)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastronex Ltd. (Italy)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • DigestCare Pharmaceuticals (South Korea)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Ulcera Pharmaceuticals (Sweden)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroCure Inc. (Brazil)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Stomax Pharmaceuticals (China)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Digestive Health Solutions (Mexico)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • MedicoDigest (Russia)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastropedia Pharmaceuticals (Argentina)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroGenix Corporation (South Africa)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments